^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lorigerlimab (MGD019)

    i
    Other names: MGD019, MGD 019, MGD-019
    Associations

    News

    Trials
    Company:
    MacroGenics
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Phase II Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • pMMR
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    2ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    3ms
    Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • pMMR
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    4ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, MacroGenics | N=278 --> 32
    Enrollment change • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    5ms
    Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Stivarga (regorafenib) • lorigerlimab (MGD019)
    6ms
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=60, Recruiting, MacroGenics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lorigerlimab (MGD019)
    6ms
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=278, Active, not recruiting, MacroGenics | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    9ms
    MGD019 DART® Protein in Unresectable/Metastatic Cancer (clinicaltrials.gov)
    P1, N=162, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    lorigerlimab (MGD019)
    11ms
    LORIKEET: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=154, Active, not recruiting, MacroGenics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    docetaxel • prednisone • lorigerlimab (MGD019)
    12ms
    A Study of Lorigerlimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, MacroGenics
    New P2 trial • Metastases
    |
    lorigerlimab (MGD019)
    1year
    CP-MGC018-02: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=278, Active, not recruiting, MacroGenics | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jun 2025
    Enrollment closed • Trial completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)
    over1year
    A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=278, Recruiting, MacroGenics | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    vobramitamab duocarmazine (MGC018) • lorigerlimab (MGD019)